tbuckley/cabot-search huggingface dataset:
A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status.
Authors: D. J. Watkins, J. Tabernero, H. Schmoll, T. Trarbach, F. J. Ramos, J. Howe, H. M. Brown, J. Clark, K. Hsu, B. D. Lu, D. Cunningham
Journal: Journal of Clinical Oncology (2011)

3501 Background: Evidence of cross-talk between EGFR and IGFR signaling pathways provide a logical rationale for combining anti-EGFR and anti-IGFR strategies in cancer treatment. A multicenter, double-blind, randomized phase II/III study of dalotuzumab in mCRC was conducted. The objective was to determine if dalotuzumab improved progression-free (PFS) and overall survival (OS) in combination with Cx and Ir in patients (pts) with wt KRAS mCRC. Methods: Eligible pts had previously failed both Ir and oxaliplatin and had progressed on or within 3 months of their last therapy. Pts were randomised to receive either MK-0646 10mg/kg weekly (q1w) or 15mg/kg loading followed by 7.5mg/kg every 2 weeks (q2w) or placebo (pbo) combined with Cx and Ir at standard dose/schedule. Pts continued on treatment until disease progression with radiological response assessments every 6 weeks. Results: The trial was stopped at the first interim analysis with 345 wt KRAS pts enrolled as neither dalotuzumab dosing regimen achieved proof-of-concept. Median PFS for all randomized wt KRAS status pts (per ITT) was 3.3 months in q1w (HR=1.41, p=0.978) and 5.4 in q2w (HR=1.22, p=0.881) vs. 5.6 in the placebo group. Median OS for wt KRAS patients (per ITT) was 10.8 months in q1w (HR=1.42, p=0.965) and 11.6 in q2w (HR=1.15, p=0.765) vs 14.0 in the pbo arm. Specific adverse events did not appear to explain the difference in PFS or OS observed. Higher rates of the following toxicities were noted in dalotuzumab treated pts when compared to pbo; decreased weight (q1w:22.4%; pbo:10.8%), dehydration (q1w:7.8%; pbo:1.8%), hyperglycemia (q1w:33.6%; q2w:40.2%; pbo:20.7%), skin exfoliation (q1w:4.3%; pbo:0%), peripheral sensory neuropathy (q2w:9.4%; pbo: 2.7%), and stomatitis (q2w:51.3%; pbo:36.9%). Biomarker analysis is ongoing to identify if a subpopulation of patients may have potentially benefitted from dalotuzumab therapy. Conclusions: The addition of MK-0646 to Cx and Ir worsened PFS and OS in pts with chemorefractory wt KRAS mCRC. Predictive biomarker analysis is ongoing to identify subpopulations.
A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC)
Authors: E. Casado, G. Folprecht, L. Paz-Ares, F. Rojo, C. H. Köhne, H. Cortes-Funes, J.-M. Vauthier, C. Zacharchuk, J. Baselga, J. Tabernero
Journal: Journal of Clinical Oncology (2004)

3543 Background: In preclinical models, EKB-569 has shown growth inhibition of EGFR-expressing colorectal tumor cell lines with at least additive inhibition when combined with chemotherapy. Methods: We have conducted a phase I/IIA study with EKB-569 used in combination with the FOLFIRI regimen as first-line treatment in pts with ACC. The objectives were to determine its safety, MTD, PK profile, antitumor activity and correlation with EGFR-signalling pathways in skin and tumors before and after treatment. Oral EKB-569 was given daily starting on day 3 of cycle 1 (28 days per cycle) with IV infusion of FOLFIRI on days 1–2 and 15–16 (CPT-11 180 mg/m2 90 min, simultaneously with LV 400 mg/m2 120 min, followed by 5FU 400 mg/m2 bolus and 2400 mg/m2 46-h continuous infusion). Pts were enrolled to receive 10, 25, 50 or 75 mg EKB-569 (3–6 pts per cohort). Dose escalation was based on safety evaluation of pt cohorts within the first 28 days. After the initial escalation, 2 cohorts were added: 35 mg EKB-569, FOLFIRI and 50 mg EKB-569, modified FOLFIRI (5FU 300 mg/m2 bolus and 2000 mg/m2 46-h continuous infusion). Results: 47 pts were included, median age 62 yrs (range 19–77) and ECOG PS 0 in 64% and 1 in 33%. DLTs were grade 3 diarrhea (2 pts in the 75-mg cohort and 2 in the 50-mg/modified FOLFIRI cohort) and grade 3 fatigue (1 in the 50-mg cohort and 1 in the 50-mg/modified FOLFIRI cohort). Limiting grade 2 diarrhea was observed in the 50-mg cohort. Thus, the MTD was selected as 25-mg EKB-569. Of 39 pts evaluable so far, the response rate is 38% and the clinical benefit rate is 85%. EKB-569 treatment resulted in complete inhibition of pEGFR and significant inhibition of pMAPK in both skin samples (11 pts) and tumor samples (3 pts) with no change in pAKT activity. Conclusions: EKB-569 combined with FOLFIRI was generally well-tolerated and showed encouraging evidence of antitumor activity and inhibition of the EGFR pathway. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Wyeth; Wyeth Research Wyeth Research
Deletion of cranial irradiation and addition of systemic high dose methotrexate and intrathecal chemotherapy results in 70% 4-yr. EFS in children and adolescents with CNS positive B-NHL: Results of International FAB/LMB 96 study
Authors: M Cairo, M Gerrard, R Sposto, A Auperin, R Pinkerton, J Michon, C Weston, S Perkins, M Raphael, K McCarthy, C Patte
Journal: Annals of Oncology (2005)
International Assessment of Atrial Fibrillation in Myocardial Infarction: The VALIANT Registry
Authors: EJ Velazquez, WS Jones, WT Smith, L Kober, R Kilaru, CB Granger, WD Weaver, G Lamas, SL Zelenkofske, PE Aylward, M Henis, K Swedberg, MA Pfeffer, Frans Van de Werf, JL Rouleau, RM Califf
Journal: Circulation (2003)
Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma
Authors: Katelyn G. Barnhart, Shannon M. Matulis, Sadae Hitosugi, Cathy Sharp, Francis Burrows, Ajay K. Nooka, Jonathan L. Kaufman, Sagar Lonial, Lawrence H. Boise
Journal: Blood (2013)
The role of alpha-fetoprotein (AFP) in monitoring of treatment and prediction of survival in patients with hepatocellular carcinoma (HCC)
Authors: S. R. Kim, H. J. Kim, Y. J. Kim
Journal: Journal of Clinical Oncology (2005)

4190 Background: The role of AFP is well established in screening of HCC, but not in monitoring of response to treatment or in predicting survival; they are still controversial in limited studies. We retrospectively analyzed the value of AFP before and after treatment in patients(pt) with HCC. Methods: Eligible pt had 1) histologically proven HCC or mass image on radiogram with liver cirrhosis and serum AFP level ≥400 ng/mL, 2) measurable tumor larger than 1.5 cm in diameter. Various prognostic factors were analyzed together with AFP levels before and after treatment, including age, sex, etiology of the disease, Child class of cirrhosis and AFP level. A maximum of 3 tumor masses were measured in two dimension. The relation of the change of AFP level to the tumor response on CT scan was also examined. Results: A total of 113 pt were analyzed. The mean age was 58.6 (36–84) and man: female was 85:28. The better prognostic factors in the survival were man, class A cirrhosis and AFP before treatment less than 400 ng/mL. The sensitivity(Se) of AFP decreased more than 50% in pt with partial remission after treatment was 85.2%, with the specificity(Sp) of 75%, positive predictability(PP) 80.6% and negative predictability(NP) of 80.8%. The Se of AFP increased more than 50% in pt with progression was 82.2%, with Sp of 81.8%, PP 86% and NP of 77.1%. There was significant association between the change of AFP level and tumor size after treatment(r=0.229, p=0.032). The survival was separately examined according to the AFP level. There was no significant difference in survival between the group with AFP less than 400 ng/mL and between 400 and 10,000; The group above 10,000 showed significantly shorter survival than two groups below 10,000 ng/mL. The group of pt with AFP decreased more than 25% survived significantly longer than the group of more than 25% increase. Conclusions: AFP seems valuable in monitoring and predicting treatment response. The initial AFP value and the change in the level may predict the prognosis of the pt with HCC. No significant financial relationships to disclose.
Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.
Authors: Elias Jabbour, Hagop Kantarjian, Susan O’Brien, Jorge Cortes, Francis Giles, Stefan Faderl, Guillermo Garcia-Manero, William Wierda, Sherry Pierce, Jianqin Shan, Elihu Estey
Journal: Blood (2005)
Bypass Surgery Versus Endovascular Therapy in Chronic Hemodialysis Patients With CLI Due to Infrainguinal Disease
Authors: Yoshitaka Kumada, Hideki Ishii, Toru Aoyama, Daisuke Kamoi, Takashi Sakakibara, Norio Umemoto, Susumu Suzuki, Hiroshi Takahashi, Toyoaki Murohara
Journal: Journal of the American College of Cardiology (2016)

Although lower limb revascularization has been commonly performed to treat critical limb ischemia (CLI) in patients with chronic kidney disease, the clinical outcomes such as limb salvage or survival rate have been reportedly poorer compared with those without chronic kidney disease after both
Abstract 2134: Standard immunohistochemistry efficiently screens for ALK rearrangements in differentiated thyroid cancer
Authors: Gahee Park, Tae Hyuk Kim, Hae-Ock Lee, Jung Ah Lim, Jae-Kyung Won, Hye Sook Min, Kyu Eun Lee, Do Joon Park, Young Joo Park, Woong-Yang Park
Journal: Cancer Research (2015)

Abstract The anaplastic lymphoma kinase (ALK) gene is frequently rearranged in various types of cancer, and is highly responsive to the target therapeutics. We developed a pipeline to detect ALK rearrangement in a large group of Korean thyroid cancer patients. We screened 474 malignant or benign thyroid tumor cases to find ALK fusion. The expression and translocation of the ALK gene were analysed by immunohistochemistry (IHC), fluorescence in situ hybridisation (FISH), and digital multiplexed gene expression (DMGE) using formalin-fixed paraffin embedded tissues. Four cases of ALK rearrangement were screened out of 474 patients by IHC, which were validated by performing FISH for 189 samples. On the other hand, DMGE analysis using Nanostring could detect three out of four IHC positive cases. Two ALK rearrangements were Striatin (STRN)-ALK fusion, identified by 5′ RACE analysis. ALK rearrangements were found exclusively in the BRAF wild type papillary carcinoma. Given the wide availability and accuracy for detecting ectopic ALK expression in the thyroid, we suggest that IHC based screening can be used as a practical method for identifying patients with ALK rearranged differentiated thyroid cancer. Citation Format: Gahee Park, Tae Hyuk Kim, Hae-Ock Lee, Jung Ah Lim, Jae-Kyung Won, Hye Sook Min, Kyu Eun Lee, Do Joon Park, Young Joo Park, Woong-Yang Park. Standard immunohistochemistry efficiently screens for ALK rearrangements in differentiated thyroid cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2134. doi:10.1158/1538-7445.AM2015-2134
Are There Differences in Treatment Patterns, Cost, and Quality Indicators By Site of Care for First Line Treatment for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (NHL/CLL)?
Authors: Adrianne W Casebeer, Sari Hopson, Dana A Drzayich Jankus, Zhuliang Tao, Stephen Stemkowski, Andrew Howe, Jeffrey Patton, Art Small, Anthony Masaquel
Journal: Blood (2015)
N0321: A phase II study of bortezomib, paclitaxel, carboplatin (CBCDA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC).
Authors: Steven E. Schild, Nathan R. Foster, Julian R. Molina, Grace K. Dy, Kendrith M. Rowland, Jann Nagina Sarkaria, Sachdev P. Thomas, Donald W. Northfelt, John William Kugler, Alex A. Adjei
Journal: Journal of Clinical Oncology (2012)

7073 Background: In preclinical studies, combinations of bortezomib and RT result in synergistic tumor killing (Cancer Chemother Pharmacol. 2007;59:207-15). Our group reported the results from the phase I portion of this study previously (J Clin Oncol. 200;28 (suppl; abstr 7085)). Based on these data, we undertook a phase II study of bortezomib in combination with paclitaxel/CBCDA and RT. Methods: Based on results from our previously reported phase I trial, systemic therapy included bortezomib (1.2 mg/m² IV days 1,4,8,11), paclitaxel (175 mg/m² IV day 2), and carboplatin (CBCDA; AUC=6 day 2) given every 3 weeks for 2 cycles. Thoracic radiotherapy (RT) included 60Gy/30 daily fractions starting day 1. The primary endpoint was the 12-month survival rate. If 41 or more of these 60 patients (68%) were alive at least 12 months after study entry, the trial would be deemed as positive and further study would be warranted. Results: 27 pts were enrolled to the phase II portion: M/F=17/10; stage IIIA/IIIB=13/14; ECOG PS 0/1=9/18; and median age: 58 (range 43-79). 18 pts (67%) completed therapy per protocol. At a planned interim analysis, 23 of 26 evaluable patients (88.5%, 95% CI: 70-98%) survived for at least 6 months, which exceeded the boundary of 21 or more needed to continue to full accrual. This trial could have continued per protocol, but was closed early due to slow accrual. With a median follow-up of 15.0 months in the 17 patients still alive, the 12-month survival rate was 71% (95% CI: 49 – 85). The median OS was 19 months (95% CI: 11 – no upper). Grade 3 or higher adverse events (regardless of attribution) were reported in 22 (82%) patients. Grade 4/5 adverse events were reported in 15 (56%) patients. There was one grade 5 event (pneumonitis). The most common (5 or more patients) grade 3/4 adverse events were fatigue (22%), leukopenia (63%), neutropenia (67%), and thrombocytopenia (44%). Conclusions: The addition of bortezomib resulted in high levels of severe hematologic toxicity, but also demonstrated evidence of activity with a 12-month survival rate of 71% and a median OS of 19 months. Further testing of this regimen in a larger study appears warranted.
Results of a 12 month multicenter trial investigating the kinetics of MPA and MPA-metabolites and the efficacy and side-effect profile of mycophenolate mofetil in renal transplant patients in view of MPA and MPA-metabolites
Authors: Drj Kuypers, Yves Vanrenterghem, JP Squifflet, M Mourad, D Abramowicz, H Oellerich, Armstrong, M Shipkova, J Daems
Journal: Journal of the American Society of Nephrology (2002)
Different innate neutrophil responses in controlled and uncontrolled asthma
Authors: Francesca Tang, Gloria Foxley, Peter Gibson, Janette Burgess, Katherine Baines, Brian Oliver
Journal: European Respiratory Journal (2015)

Introduction: Respiratory viruses are a major cause of asthma exacerbations. Neutrophilic inflammation occurs during infections and is associated with difficult to treat asthma. The role of neutrophils in viral infections and whether neutrophil dysfunction contributes to exacerbation pathogenesis remains unclear. Aim: We aimed to investigate neutrophil immune responses in controlled (CA) and uncontrolled asthma (UnCA). We hypothesised that neutrophils from UnCA but not CA have impaired immune responses. Methods: Peripheral blood neutrophils from patients with CA (ACQ0.75) (n=7) or nonasthmatics (NA) (n=9) were stimulated with bacterial (LPS (1μg/ml), fMLP (100nM)) and viral surrogates( imiquimod (3μg/ml), R848 (1.5μg/ml), poly I:C (10μg/ml)) or rhinovirus (RV)16 (multiplicity of infection 1). Cell free supernatant was collected after 1h for measurement of neutrophil elastase (NE) by a colourimetric activity assay and matrix metalloproteinase (MMP)-9 by zymography or after 24h for CXCL8 release by ELISA. Results: fMLP stimulated neutrophils from UnCA but not CA had a 70% reduction in CXCL8 compared to NA. fMLP induced MMP9 release was also impaired by 50% in UnCA and 30% in CA compared to NA. Enhanced NE release (double) occurred constitutively and with fMLP stimulation in neutrophils from CA compared to NA. Interestingly, RV16 induced CXCL8 and R848 induced MMP-9 in CA and UnCA but not NA neutrophils. UnCA and CA responded similarly to other stimuli. Conclusion: Impaired innate responses in neutrophils from UnCA occurred only with the bacterial toxin fMLP, this might allow certain bacteria to colonise the airways and contribute to an altered lung microbiome in UnCA.
FRI0547 Magnetic Resonance Imaging Joint Space Narrowing Is An Independent Predictor of Radiographic and MRI Damage Progression in Patients with Early Rheumatoid Arthritis: Table 1
Authors: S. Møller-Bisgaard, B. Ejbjerg, I. Eshed, K. Hørslev-Petersen, M. Hetland, A.G. Jurik, H. Thomsen, T. Torfing, K. Stengaard-Pedersen, P. Junker, N.S. Krogh, T. Lottenburger, T. Ellingsen, L.S. Andersen, H. Skjødt, A. Svendsen, U. Tarp, I. Hansen, J. Pødenphant, J.K. Pedersen, H. Lindegaard, A. Vestergaard, D. Glinatsi, M. Østergaard
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Magnetic Resonance Imaging (MRI) osteitis and synovitis have been identified as predictors of structural damage progression in rheumatoid arthritis (RA)<sup>1,2</sup>, but the predictive value of MRI joint space narrowing (JSN, a measure of cartilage damage) and tenosynovitis (TS) needs further investigation. <h3>Objectives</h3> To investigate the predictive value of baseline MRI inflammatory and damage parameters on 2 year MRI and X-ray damage progression in an early RA (eRA) cohort following a non biologic treat-to-target strategy. <h3>Methods</h3> In 129 eRA (&lt;6months) patients from the double-blind randomized CIMESTRA trial (methotrexate, intraarticular betamethasone and cyclosporine (CYA)/placebo CYA) contrast-enhanced MRIs of the non-dominant wrist and X-rays of hands and feet were performed at baseline and after 2 years. MRIs were evaluated according to the RAMRIS scoring system for osteitis, synovitis, erosion (ES), JSN, for TS<sup>3</sup> and X-rays according to the Sharp/van der Heijde method, with known chronology by two experienced radiologists. Potential predictive baseline variables (MRI osteitis, synovitis, TS, ES, JSN, X-ray ES and JSN, DAS28, gender, age, anti-CCP, smoking status) were tested in univariate linear regression analyses with 2-year change in MRI total damage score, Total Sharp Score (TSS), and MRI and X-ray JSN and ES scores as dependent variables. Significant variables (p&lt;0.05) were included in multiple regression analyses with backward selection. <h3>Results</h3> Independent predictors of structural damage progression are presented in table 1. If MRI JSN was not included in the model, MRI osteitis score was statistically significant independent predictor of X-ray progression (coefficient 0.32, p=0.001, vs TSS progression). <h3>Conclusions</h3> This trial is the first to report that MRI JSN independently predicts both X-ray and MRI damage progression in early RA. Further studies are needed to confirm early MRI-determined cartilage damage as predictor of progressive joint destruction in RA. <h3>References</h3> Hetland et al, Ann Rheum Dis 2009 Boyesen et al, Ann Rheum Dis 2011 Haavardsholm et al, Ann Rheum Dis 2007 <h3>Disclosure of Interest</h3> None declared
Sensitivity Analyses of Progression-Free Survival (PFS) of Aflibercept-Folfiri Versus Placebo-Folfiri in Metastatic Colorectal Cancer (MCRC): Results from the Velour Study
Authors: E. Van Cutsem, J. Tabernero, R. Lakomy, J. Prausova, P. Ruff, V. Moiseyenko, D. Ferry, E. Boelle, J. McKendrick, C. Allegra
Journal: Annals of Oncology (2012)
Antibodies to S-303 Treated RBC Prepared with the Original Treatment Process (OSRBC) for Pathogen Inactivation Do Not React with RBC Prepared with a Modified S-303 Treatment Process (MSRBC).
Authors: Maureen G. Conlan, George Garratty, Grace Castro, Anna Erickson, Mary Ann Schott, Pat Arndt, David Cook, Laurence Corash, Adonis Stassinopoulos
Journal: Blood (2005)
Relationship of efficacy with kras status (wild type [wt] vs mutant [mt]) in patients with irinotecan-refractory metastatic colorectal cancer (mcrc), treated with irinotecan and escalating doses of cetuximab: preliminary data from the everest study
Authors: Sabine Tejpar, M Peeters, H Gelderblom, Y Humblet, J Vermorken, G De Hertogh, J Nippgen, A von Heydebreck, C Stroh, Eric Van Cutsem
Journal: Annals of Oncology (2008)
Childhood cancer: Do females experience more acute toxicities than males? A report from the Children's Oncology Group.
Authors: K. A. Meeske, L. Ji, A. Butturini, D. R. Freyer, P. S. Gaynon, K. Ruccione, R. Sposto, N. L. Seibel, S. E. Siegel
Journal: Journal of Clinical Oncology (2010)

9515 Background: Drug dosing is based on a gender-independent estimate of body surface area. In childhood acute lymphoblastic leukemia (ALL), females have a consistently better event-free survival than males. However, long-term follow-up studies often find an increase in treatment-related late effects among female cancer survivors. The purpose of this study is to determine if females also experience more acute toxicities during active treatment. Methods: We reviewed data collected on the Children's Cancer Group (CCG) high-risk ALL study, CCG-1961. We studied 830 female and 1,224 male patients enrolled between 1996 and 2002, ages 1-21 years. Linear and logistic regression were used to analyze differences in hospital days, length of treatment courses, incidence of grade 3 and 4 toxicities (CCG Toxicity Rating Scale) and reported supportive care use between males and females for the first four phases of treatment. Analyses were adjusted for age, race, treatment regimen, phase and body surface area. Results: Females had significantly more hospital days than males (D1.6, 1.3, 1.2 and 1.4 days, p<0.001,<0.01,<0.001 and <0.001, for Induction, Consolidation, Interim Maintenance and Delayed Intensification, respectively). Females had more grade 3 and 4 toxicities: nervous system (OR=1.6, p<0.01), gastrointestinal (OR=1.6, p<0.0001), pancreas (OR=1.7, p<0.0001), and infections (OR=1.6, p<0.001). Risk of having therapy delayed more than a week due to treatment-related toxicities was significantly higher for females (OR=1.2, p<0.02). Females received more IV antibiotics (OR=1.2, p<0.01), IV antifungals (OR=1.7, p<0.0001), IV analgesics (OR=1.3, p<0.05), parenteral nutrition (OR=1.9, p<0.0001) and blood products (OR=1.8, p<0.0001). Conclusions: Females treated on CCG-1961 experienced more acute toxicities than males. It appears that female pediatric cancer patients may be at higher risk of developing both acute and long-term complications. Sex-specific differences in outcomes may be due to factors such as differences in body composition, endogenous hormones and drug metabolism. Further study is needed to better understand the disparities in treatment-related toxicities found among male and female pediatric cancer patients. No significant financial relationships to disclose.
Prospective Phase II Study Using Dexamethasone Induction Therapy and High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Transplantation in 30 Patients with Systemic AL Amyloidosis.
Authors: Stefan Schonland, Ute Hegenbart, Axel Benner, Jolanta Perz, Tilmann Bochtler, Jörg Beimler, Martin Zeier, Arnt Kristen, Anthony D. Ho, Hartmut Goldschmidt
Journal: Blood (2009)
Potential Biomarkers for Response to Cetuximab in Patients with Metastatic Colorectal Cancer (MCRC). A Hellenic Cooperative Oncology Group Study
Authors: E. Razis, M. Bobos, W. De Roock, M. Bai, A. Gousia, I. Xanthakis, E. Tsolaki, P. Papakostas, S. Tejpar, G. Fountzilas
Journal: Annals of Oncology (2012)
Considerations for Developing a Zika Virus Vaccine
Authors: Hilary D. Marston, Nicole Lurie, Luciana L. Borio, Anthony S. Fauci
Journal: New England Journal of Medicine (2016)

The scientific feasibility of developing a safe, effective Zika vaccine doesn't ensure successful development. An efficient development pathway must be delineated, including better ways to evaluate vaccine candidates for intended target populations.